Literature DB >> 1913475

Malignant histiocytosis X. A distinct clinicopathologic entity.

J Ben-Ezra1, A Bailey, N Azumi, G Delsol, R Stroup, K Sheibani, H Rappaport.   

Abstract

Histiocytosis X (HX) is characterized morphologically by a proliferation of Langerhans' cells (LC), and most often has an indolent, chronic course. To determine whether a distinct clinicopathologic entity of malignant histiocytosis X exists, the authors examined tissues from 31 patients with HX and divided them into four categories. Group A (19 patients) was characterized morphologically by benign-appearing LC and had an indolent course. The male:female (M:F) ratio was 10:9, and the mean age was 21 years (range, 2 months to 60 years). The immunophenotype of this group was S-100+, vimentin+, LN-2+, LN-3+, lysozyme-, LCA-, Leu-M1-. Group B (three patients) had benign-appearing LC, yet had an aggressive clinical course. All patients were male, with a mean age of 47 years (range, 3 years to 72 years). Organs involved included the liver, spleen, heart, thymus, lung, kidney, and pancreas. The immunophenotype was the same as for Group A. Group C (two patients) had atypical and malignant appearing LC, yet a relatively benign clinical course. The ages were four and 65 years, with one female and one male patient. In both patients, the cells were S-100+, vimentin+, LN-2+, LN-3+, and LCA-. Group D (seven patients) was characterized by atypical and malignant-appearing LC and an aggressive clinical course. The mean age was 25 years (range, congenital to 54 years) with one female and six male patients. Organs involved were the thymus, lungs, spleen, liver, kidney, brain, heart, pancreas, stomach, and muscle. Birbeck granules were found in two patients, and the one patient on which fresh tissue was available was CD1+. The typical immunophenotype was S-100+, vimentin+, LN-2+, LN-3+, Leu-M1-, lysozyme-. The results of our study indicate that (1) a distinct clinical entity of malignant HX, characterized morphologically by malignant-appearing LC and clinically by male predominance, atypical organ involvement, and an aggressive clinical course, does exist; and (2) the morphologic appearance of the LC is an imperfect predictor of the clinical severity of HX.

Entities:  

Mesh:

Year:  1991        PMID: 1913475     DOI: 10.1002/1097-0142(19910901)68:5<1050::aid-cncr2820680524>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Pulmonary manifestation of a Langerhans cell sarcoma: case report and review of the literature.

Authors:  Boris Dominik Jülg; Sven Weidner; Doris Mayr
Journal:  Virchows Arch       Date:  2005-11-22       Impact factor: 4.064

Review 2.  Cutaneous Langerhans cell sarcoma: a case report and review of the literature.

Authors:  Olga L Bohn; Guillermo Ruiz-Argüelles; Leticia Navarro; Jesus Saldivar; Sergio Sanchez-Sosa
Journal:  Int J Hematol       Date:  2007-02       Impact factor: 2.490

3.  CD56/NCAM-positive Langerhans cell sarcoma: a clinicopathologic study of 4 cases.

Authors:  Takakazu Kawase; Minoru Hamazaki; Michinori Ogura; Yoshiaki Kawase; Toshihiko Murayama; Yoshio Mori; Hirokazu Nagai; Masatoshi Tateno; Takashi Oyama; Yoshikazu Kamiya; Hirofumi Taji; Yoshitoyo Kagami; Tomoki Naoe; Toshitada Takahashi; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2005-05       Impact factor: 2.490

4.  Langerhans cell sarcoma arising from Langerhans cell histiocytosis: a case report.

Authors:  Jong-Sil Lee; Gyung Hyuck Ko; Ho Cheol Kim; In Seok Jang; Kyung-Nyeo Jeon; Jeong-Hee Lee
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

5.  ESHAP therapy effective in a patient with Langerhans cell sarcoma.

Authors:  Akihide Yoshimi; Keiki Kumano; Toru Motokura; Yutaka Takazawa; Satoshi Oota; Shigeru Chiba; Tsuyoshi Takahashi; Masashi Fukayama; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2008-04-17       Impact factor: 2.490

6.  Recurrent Indeterminate Dendritic Cell Tumor of the Skin.

Authors:  Jin Woo Joo; Taek Chung; Yoon Ah Cho; Sang Kyum Kim
Journal:  J Pathol Transl Med       Date:  2018-04-05

7.  Unusual cutaneous Langerhans cell sarcoma without extracutaneous involvement.

Authors:  Yang Li; Bin Li; Xiao-ying Tian; Zhi Li
Journal:  Diagn Pathol       Date:  2013-02-06       Impact factor: 2.644

Review 8.  Multifocal Langerhans cell sarcoma involving epidermis: a case report and review.

Authors:  Changsong Wang; Yanping Chen; Chunfang Gao; Jian Yin; Hong Li
Journal:  Diagn Pathol       Date:  2012-08-14       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.